Latest On Guardant Health, Inc (GH):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-30 15:17 EST | News | Guardant Health gains amid activist speculation | N/A |  |
| 2023-05-26 11:32 EST | News | Guardant Health gains as Citi upgrades citing a “cleaner” narrative | N/A | |
| 2023-05-23 12:54 EST | News | Guardant dips after pricing $350M stock offering | N/A | |
| 2023-05-22 22:16 EST | News | Guardant Health proposes $250M stock offering, shares fall | N/A | |
| 2023-05-10 16:14 EST | News | Guardant surges ~10% after clinical testing drives Q1 revenue; raises outlook | N/A | |
About Guardant Health, Inc (GH):
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay read more...with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
General
- Name Guardant Health, Inc
- Symbol GH
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDiagnostics & Research
- Full Time Employees 864
- Fiscal Year EndDecember
- IPO Date2018-10-04
- Gic SectorHealth Care
- Gic GroupHealth Care Equipment & Services
- Gic IndustryHealth Care Providers & Services
- Gic SubIndustryHealth Care Services
- Web URLhttp://guardanthealth.com
Valuation
- Price/Sales (Trailing 12 Mt.) 49.29
- Price/Book (Most Recent Quarter) 11.21
- Enterprise Value Revenue 47.49
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$3.61
- Next Year EPS Estimate -$3.03
- Next Quarter EPS Estimate -$0.48
- Profit Margin -89%
- Operating Margin -86%
- Return on Assets -9%
- Return on Equity -22%
- Revenue 286.73 million
- Earnings Per Share -$1.28
- Revenue Per Share $2.94
- Gross Profit 194.2 million
- Quarterly Earnings Growth 24.5%
Highlights
- Market Capitalization 14.65 billion
- EBITDA -81341000
- PE Ratio -6.41
- Analyst Target Price $177.8
- Book Value Per Share $12.96
Share Statistics
- Shares Outstanding 100.43 million
- Shares Float 88.3 million
- % Held by Insiders 776%
- % Held by Institutions 79.64%
- Shares Short 3.84 million
- Shares Short Prior Month 3.71 million
- Short Ratio 3.69
- Short % of Float 6%
- Short % of Shares Outstanding 4%
Technicals
- Beta 0.5
- 52 Week High $180.83
- 52 Week Low $58.28
- 50 Day Moving Average 154.01
- 200 Day Moving Average 126.94
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Guardant Health, Inc (GH) Dividend Calendar:
Guardant Health, Inc (GH) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Guardant Health, Inc (GH) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Guardant Health, Inc (GH) Chart:
Guardant Health, Inc (GH) News:
Below you will find a list of latest news for Guardant Health, Inc (GH) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Guardant Health, Inc (GH) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest GH Trades:
Guardant Health, Inc (GH) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-27 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-13 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-13 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-10-13 | 8-K (Current report) | |
| 2020-10-08 | 424B7 (Prospectus [Rule 424(b)(7)]) | |
| 2020-10-06 | 8-K/A (Current report) | |
| 2020-10-06 | 424B7 (Prospectus [Rule 424(b)(7)]) | |
| 2020-10-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-29 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-14 | 4 (Statement of changes in beneficial ownership of securities) | |
Guardant Health, Inc (GH) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Guardant Health, Inc (GH). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 776%
Institutional Ownership: 7964%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-11-03 | IAN T CLARK | Director | Sell | 2,690.00 | 105.28 | 283,203.20 | 4,643.00 | |
| 2020-11-03 | IAN T CLARK | Director | Buy | 2,690.00 | 4.18 | 11,244.20 | 7,333.00 | |
| 2020-10-27 | AmirAli Talasaz | Chairman, President and COO | Sell | 3,400.00 | 110.03 | 374,111.86 | 620,800.00 | |
| 2020-10-27 | AmirAli Talasaz | Chairman, President and COO | Sell | 10,000.00 | 109.28 | 1,092,834.00 | 624,200.00 | |
| 2020-10-27 | AmirAli Talasaz | Chairman, President and COO | Sell | 13,272.00 | 108.19 | 1,435,937.50 | 634,200.00 | |
| 2020-10-27 | AmirAli Talasaz | Chairman, President and COO | Sell | 9,678.00 | 107.44 | 1,039,819.80 | 647,472.00 | |
| 2020-10-27 | AmirAli Talasaz | Chairman, President and COO | Sell | 25,263.00 | 106.35 | 2,686,800.89 | 657,150.00 | |
| 2020-10-27 | AmirAli Talasaz | Chairman, President and COO | Sell | 14,238.00 | 105.35 | 1,500,037.37 | 682,413.00 | |
| 2020-10-26 | IAN T CLARK | Director | Sell | 538.00 | 104.03 | 55,968.14 | 4,643.00 | |
| 2020-10-26 | IAN T CLARK | Director | Buy | 538.00 | 4.18 | 2,248.84 | 5,181.00 | |
| 2020-10-26 | AmirAli Talasaz | Chairman, President and COO | Sell | 4,613.00 | 105.02 | 484,472.48 | 696,651.00 | |
| 2020-10-23 | AmirAli Talasaz | Chairman, President and COO | Sell | 13,136.00 | 105.15 | 1,381,314.77 | 701,264.00 | |
| 2020-10-16 | Samir Kaul | Director | Sell | 1,575.00 | 103.21 | 162,562.05 | 51,943.00 | |
| 2020-10-16 | Samir Kaul | Director | Sell | 3,215.00 | 102.19 | 328,532.17 | 53,518.00 | |
| 2020-10-16 | Samir Kaul | Director | Sell | 5,210.00 | 101.29 | 527,699.02 | 56,733.00 | |
| 2020-10-16 | AmirAli Talasaz | Chairman, President and COO | Sell | 1,801.00 | 103.45 | 186,313.63 | 714,400.00 | |
| 2020-10-16 | AmirAli Talasaz | Chairman, President and COO | Sell | 11,000.00 | 102.89 | 1,131,783.40 | 716,201.00 | |
| 2020-10-16 | AmirAli Talasaz | Chairman, President and COO | Sell | 10,599.00 | 101.81 | 1,079,035.43 | 727,201.00 | |
| 2020-10-12 | STANLEY J MERESMAN | Director | Sell | 5,000.00 | 109.37 | 546,850.00 | 4,059.00 | |
| 2020-10-12 | STANLEY J MERESMAN | Director | Buy | 5,000.00 | 5.94 | 29,700.00 | 9,059.00 | |